Posted by Michael Wonder on 07 Oct 2024
Health Canada approves label expansion for Telix’s Illuccix to include patient selection for PSMA targeted therapy
4 October 2024 - Telix Pharmaceuticals today announces that Health Canada has approved the use of Illuccix (kit for the preparation of gallium Ga 68 gozetotide injection) in selecting patients for PSMA targeted radionuclide therapy.
The label expansion means that Illuccix is now approved in Canada to select patients with progressive metastatic castration-resistant prostate cancer for treatment with the only approved PSMA targeted radionuclide therapy (lutetium (Lu 177) vipivotide tetraxetan, or Pluvicto). To qualify for PSMA targeted therapy, patients must be imaged with an approved gallium based PSMA PET3 agent , such as Illuccix.
